Loading...

Amir Goldkorn, MD

TitleAssociate Professor of Medicine
InstitutionUniversity of Southern California
DepartmentMedicine
AddressNOR 3444
Health Sciences Campus
Los Angeles CA 90089-9173
Phone+1 323 442 7721
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    Harvard University1990  - 1994Harvard College Scholarship
    UCLA School of Medicine1996  - 1997Letters of Distinction
    American Society of Clinical Oncology2006  - 2007Young Investigator Award
    Stop Cancer Foundation2007  - 2010Research Career Development Award
    American Society of Clinical Oncology2012Merit Award
    Western Society of Clinical Investigation2014Elected Member
    American Federation for Medical Research2015Outstanding Investigator Award
    National Institutes of Health Loan Repayment Program Award

    Collapse Overview 
    Collapse Overview
    Dr. Goldkorn’s laboratory-based research program focuses on developing the therapeutic and biomarker potential of circulating tumor cells, cancer stem cells, and telomerase. Graduate students, postdocs and medical students in the laboratory conduct experiments ranging from basic molecular research to translational medicine assays for clinical trials. These research activities synergize with our clinical activities and provide unique opportunities to translate our laboratory and clinical advances into better care for our patients.

    Dr. Goldkorn earned his medical degree from the UCLA School of Medicine. He then went on to complete his fellowship in hematology-oncology and post-doctoral research at University of California, San Francisco.


    Collapse Research 
    Collapse Research Activities and Funding
    Biomarkers of Hormone Therapy Response in a Multicenter Prostate Cancer Trial
    NIH/NCI R01CA172436Sep 10, 2014 - Aug 31, 2019
    Role: Principal Investigator
    Circulating Tumor Cell Capture &Analysis in a Multi-Center Prostate Cancer Trial
    NIH/NCI R01CA141077Sep 18, 2009 - Aug 31, 2014
    Role: Co-Principal Investigator
    Targeting Cancer with Telomerase Interference
    NIH/NCI K08CA126983Sep 1, 2007 - Aug 31, 2012
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Liu SV, Groshen SG, Kelly K, Reckamp KL, Belani C, Synold TW, Goldkorn A, Gitlitz BJ, Cristea MC, Gong IY, Semrad TJ, Xu Y, Xu T, Koczywas M, Gandara DR, Newman EM. A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 Aug 20. PMID: 30128950.
      View in: PubMed
    2. Meeks JJ, Goldkorn A, Aparicio AM, McConkey DJ. Development of a translational medicine protocol for an NCTN genitourinary clinical trial: Critical steps, common pitfalls and a basic guide to translational clinical research. Urol Oncol. 2018 Aug 13. PMID: 30115512.
      View in: PubMed
    3. Morrison GJ, Goldkorn A. Development and Application of Liquid Biopsies in Metastatic Prostate Cancer. Curr Oncol Rep. 2018 Mar 23; 20(4):35. PMID: 29572775.
      View in: PubMed
    4. Zainfeld D, Goldkorn A. Liquid Biopsy in Prostate Cancer: Circulating Tumor Cells and Beyond. Cancer Treat Res. 2018; 175:87-104. PMID: 30168118.
      View in: PubMed
    5. Sonpavde G, Pond GR, Plets M, Tangen CM, Hussain MHA, Lara PN, Goldkorn A, Garzotto MG, Mack PC, Higano CS, Vogelzang NJ, Thompson IM, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Quinn DI. Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer. 2017 Dec; 15(6):635-641. PMID: 28579151.
      View in: PubMed
    6. Hugen CM, Zainfeld DE, Goldkorn A. Circulating Tumor Cells in Genitourinary Malignancies: An Evolving Path to Precision Medicine. Front Oncol. 2017; 7:6. PMID: 28191452.
      View in: PubMed
    7. Xu Y, Goldkorn A. Telomere and Telomerase Therapeutics in Cancer. Genes (Basel). 2016 May 26; 7(6). PMID: 27240403; PMCID: PMC4929421.
    8. Hu BR, Fairey AS, Madhav A, Yang D, Li M, Groshen S, Stephens C, Kim PH, Virk N, Wang L, Martin SE, Erho N, Davicioni E, Jenkins RB, Den RB, Xu T, Xu Y, Gill IS, Quinn DI, Goldkorn A. AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth. Prostate. 2016 May; 76(6):597-608. PMID: 26771938.
      View in: PubMed
    9. Goldkorn A. Editorial Comment. J Urol. 2015 Sep; 194(3):798. PMID: 26072034.
      View in: PubMed
    10. Challagundla KB, Wise PM, Neviani P, Chava H, Murtadha M, Xu T, Kennedy R, Ivan C, Zhang X, Vannini I, Fanini F, Amadori D, Calin GA, Hadjidaniel M, Shimada H, Jong A, Seeger RC, Asgharzadeh S, Goldkorn A, Fabbri M. Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy. J Natl Cancer Inst. 2015 Jul; 107(7). PMID: 25972604; PMCID: PMC4651042.
    11. Goldkorn A, Ely B, Tangen CM, Tai YC, Xu T, Li H, Twardowski P, Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Garzotto M, Mack PC, Lara P, Higano CS, Hussain M, Vogelzang NJ, Thompson IM, Cote RJ, Quinn DI. Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer. 2015 Apr 15; 136(8):1856-62. PMID: 25219358; PMCID: PMC4323674.
    12. Hu B, Goldkorn A. Circulating tumor cells in prostate cancer: a better predictor of survival than prostate specific antigen? Expert Rev Anticancer Ther. 2014 Nov; 14(11):1257-60. PMID: 25199875.
      View in: PubMed
    13. Agarwal N, Dorff T, Goldkorn A. New prostate cancer drugs: extending and improving life. Lancet Oncol. 2014 Sep; 15(10):1052-4. PMID: 25104108.
      View in: PubMed
    14. Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Datar RH, Garzotto M, Mack PC, Lara P, Higano CS, Hussain M, Thompson IM, Cote RJ, Vogelzang NJ. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol. 2014 Apr 10; 32(11):1136-42. PMID: 24616308; PMCID: PMC3970171.
    15. Lara PN, Ely B, Quinn DI, Mack PC, Tangen C, Gertz E, Twardowski PW, Goldkorn A, Hussain M, Vogelzang NJ, Thompson IM, Van Loan MD. Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421. J Natl Cancer Inst. 2014 Apr; 106(4):dju013. PMID: 24565955; PMCID: PMC3982883.
    16. Hu B, Rochefort H, Goldkorn A. Circulating tumor cells in prostate cancer. Cancers (Basel). 2013 Dec 04; 5(4):1676-90. PMID: 24305656; PMCID: PMC3875960.
    17. Dorff TB, Tsao-Wei DD, Groshen S, Boswell W, Goldkorn A, Xiong S, Quinn DI, Pinski JK. Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2013 Dec; 11(4):416-22. PMID: 24099865.
      View in: PubMed
    18. He K, Xu T, Xu Y, Ring A, Kahn M, Goldkorn A. Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/ß-catenin/CBP pathway. Int J Cancer. 2014 Jan 01; 134(1):43-54. PMID: 23784558.
      View in: PubMed
    19. Quinn DI, Tangen CM, Hussain M, Lara PN, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol. 2013 Aug; 14(9):893-900. PMID: 23871417; PMCID: PMC4277263.
    20. Cho HY, Wang W, Jhaveri N, Torres S, Tseng J, Leong MN, Lee DJ, Goldkorn A, Xu T, Petasis NA, Louie SG, Schönthal AH, Hofman FM, Chen TC. Perillyl alcohol for the treatment of temozolomide-resistant gliomas. Mol Cancer Ther. 2012 Nov; 11(11):2462-72. PMID: 22933703.
      View in: PubMed
    21. Xu Y, He K, Goldkorn A. Telomerase targeted therapy in cancer and cancer stem cells. Clin Adv Hematol Oncol. 2011 Jun; 9(6):442-55. PMID: 21841744.
      View in: PubMed
    22. He K, Xu T, Goldkorn A. Cancer cells cyclically lose and regain drug-resistant highly tumorigenic features characteristic of a cancer stem-like phenotype. Mol Cancer Ther. 2011 Jun; 10(6):938-48. PMID: 21518726; PMCID: PMC3112267.
    23. Xu T, He K, Wang L, Goldkorn A. Prostate tumor cells with cancer progenitor properties have high telomerase activity and are rapidly killed by telomerase interference. Prostate. 2011 Sep 15; 71(13):1390-400. PMID: 21321978; PMCID: PMC3123672.
    24. Xu T, Lu B, Tai YC, Goldkorn A. A cancer detection platform which measures telomerase activity from live circulating tumor cells captured on a microfilter. Cancer Res. 2010 Aug 15; 70(16):6420-6. PMID: 20663903; PMCID: PMC2922429.
    25. Xu T, Xu Y, Liao CP, Lau R, Goldkorn A. Reprogramming murine telomerase rapidly inhibits the growth of mouse cancer cells in vitro and in vivo. Mol Cancer Ther. 2010 Feb; 9(2):438-49. PMID: 20124445; PMCID: PMC2820598.
    26. Dorff TB, Goldkorn A, Quinn DI. Targeted therapy in renal cancer. Ther Adv Med Oncol. 2009 Nov; 1(3):183-205. PMID: 21789121; PMCID: PMC3125999.
    27. Goldkorn A, Blackburn EH. Assembly of mutant-template telomerase RNA into catalytically active telomerase ribonucleoprotein that can act on telomeres is required for apoptosis and cell cycle arrest in human cancer cells. Cancer Res. 2006 Jun 01; 66(11):5763-71. PMID: 16740715.
      View in: PubMed